Clinical Trial Update: Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation [Phase 2]

View source ↗

Summary

Phase 2 study evaluating lumacaftor alone and in combination with ivacaftor in cystic fibrosis patients with the F508del-CFTR mutation; results were posted afte…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Ivacaftor (ivacaftor)
• Lumacaftor (lumacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2015-10-05